Australia markets closed
  • ALL ORDS

    7,490.10
    -178.80 (-2.33%)
     
  • ASX 200

    7,175.80
    -166.60 (-2.27%)
     
  • AUD/USD

    0.7187
    -0.0041 (-0.56%)
     
  • OIL

    84.83
    -0.72 (-0.84%)
     
  • GOLD

    1,836.10
    -6.50 (-0.35%)
     
  • BTC-AUD

    49,735.42
    +60.55 (+0.12%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • AUD/EUR

    0.6333
    -0.0054 (-0.85%)
     
  • AUD/NZD

    1.0702
    +0.0008 (+0.07%)
     
  • NZX 50

    12,348.00
    -149.10 (-1.19%)
     
  • NASDAQ

    14,438.40
    -408.06 (-2.75%)
     
  • FTSE

    7,494.13
    -90.88 (-1.20%)
     
  • Dow Jones

    34,265.37
    -450.02 (-1.30%)
     
  • DAX

    15,603.88
    -308.45 (-1.94%)
     
  • Hang Seng

    24,965.55
    +13.20 (+0.05%)
     
  • NIKKEI 225

    27,522.26
    -250.67 (-0.90%)
     

Global Anatomic Pathology Market to Grow by $14 Billion during 2021-2026 - Anatomic Pathology Services, Disease Diagnostics, Hospital Labs, and Asia-Pacific are the Lucrative Segments

·3-min read

Dublin, Nov. 29, 2021 (GLOBE NEWSWIRE) -- The "Anatomic Pathology Market by Product & Service, Application, End-user, and Region - Global Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.

The global anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7%.

The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on personalized medicine. In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period.

The anatomic pathology services segment accounted for the highest growth rate in the anatomic pathology market, by product and service, during the forecast period

Based on product & service, the anatomic pathology market is segmented into services, consumables, and instruments. The anatomic pathology services segment is projected to register the highest CAGR during the forecast period. The growth of this segment is primarily driven by rapid growing geriatric population and the increasing incidence of cancer and other chronic diseases.

Disease Diagnostics accounted for the highest CAGR

Based on application, the anatomic pathology market is segmented into disease diagnostics and medical research. The disease diagnostics segment is projected to register the highest CAGR during the forecast period. This can be attributed to rising geriatric population and the increasing incidence of cancer and other chronic diseases.

Hospital laboratories accounted for the highest CAGR

Based on end-user, the anatomic pathology market is segmented into hospital laboratories, clinical laboratories, and other end users. Hospital laboratories is projected to register the highest CAGR during the forecast period. Increasing number of patient visits to hospitals, the growing number of in-house diagnostic procedures performed in hospitals, and growing awareness regarding early disease diagnosis are major factors contributing to growth of the segment.

Asia Pacific: The fastest-growing region in the Anatomic pathology market

The anatomic pathology market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The Asia Pacific region offers high-growth opportunities for players in the anatomic pathology market. The presence of emerging economies like China and India, the large population in APAC countries, rising prevalence of chronic diseases, improving standard of living, growing demand for quality medical care, increasing healthcare spending and government initiatives, and rising awareness about the use of anatomic pathology tests among physicians are the major factors driving market growth in the Asia Pacific region.

Research Coverage

This report provides a detailed picture of the anatomic pathology market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, application, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Market Dynamics

  • Drivers

    • High Incidence of Cancer and Other Target Diseases

    • Recommendations for Cancer Screening

    • Availability of Reimbursement

    • Growing Focus on Personalized Medicine

  • Opportunities

    • Increasing Number of Clinical Trials Pertaining to Cancer Drugs

    • Emerging Markets Offer Lucrative Opportunities

    • Companion Diagnostics

  • Challenges

    • Availability of Refurbished Products

    • Lack of Skilled Professionals

    • Product Failures and Recalls

    • Inadequate Infrastructure and Low Awareness in Middle- and Low-Income Countries

  • Trends

    • Reagent Rental Agreements

Companies Profiled

  • Abcam plc

  • Agilent Technologies

  • Amos Scientific Pty. Ltd.

  • Becton, Dickinson and Company

  • Bio SB

  • Biogenex

  • Bright Instruments

  • Cell Signaling Technology

  • Cellpath Ltd.

  • Danaher Corporation

  • Diapath S.p.A.

  • F. Hoffman-La Roche Ltd.

  • Histo-Line Laboratories

  • Hologic, Inc.

  • Jinhua Yidi Medical Appliance Co. Ltd.

  • Lupetec

  • Medimeas

  • Medite Medical GmbH

  • Merck KGaA

  • Micros Austria

  • Milestone Medical

  • PHC Holdings Corporation

  • R. K. Scientific Instrument Private Limited

  • Sakura Finetek USA Inc.

  • Slee Medical GmbH

For more information about this report visit https://www.researchandmarkets.com/r/tvru1n

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting